< Back to previous page
Researcher
Wim Laleman
- Disciplines:Gastro-enterology and hepatology, Immunology, Paediatrics and neonatology, Nursing
Affiliations
- Hepatology (Division)
Member
From1 Oct 2002 → 30 Sep 2022
Projects
1 - 8 of 8
- Design of robotic catheter and endoscopic systems for cancer treatmentFrom16 Feb 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stratifying risk and individualizing care for patients with clinically significant portal hypertension (CSPH)From7 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Acute-on-chronic liver failure (ACLF): monocyte profiles as a predictor for progression or recovery signatures in patients.From1 Dec 2019 → 31 May 2020Funding: Private funding of national origin - undefined
- MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment responseFrom1 Jan 2019 → TodayFunding: H2020 - Health, demographic change and wellbeing
- Deciphering the molecular pathways needed to restore monocyte dysfunction during Acute-on-chronic liver failureFrom1 Oct 2018 → 30 Sep 2022Funding: BOF - Concerted Research Project from 1994
- Characterisation of the human gut virome in patients with liver steatosis in order to identify biomarkers for diagnosis and targets for drug development.From1 Oct 2018 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- A cell-by-cell analysis of the systemic and hepatic landscape during Acute-on-Chronic Liver Failure.From13 Sep 2018 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role of microcirculatory dysfunction, the innate immune system and intestinal permeability in the early onset of acute-on-chronic liver failure.From1 Oct 2010 → 30 Sep 2015Funding: FWO fellowships
Publications
1 - 10 of 285
- Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis(2024)
Authors: Wim Laleman
- Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.(2024)
Authors: Wim Laleman
Pages: e079309 - The outcomes and safety of patients undergoing endoscopic retrograde cholangiopancreatography combining a single-use cholangioscope and a single-use duodenoscope: A multicenter retrospective international study(2024)
Authors: Wim Laleman
Pages: 71 - 76 - Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis(2024)
Authors: Geert Maleux, Wim Laleman
- Outcomes of minor versus major papilla rendez-vous for EUS-guided pancreatic duct drainage(2024)
Authors: Hannah van Malenstein, Wim Laleman, Schalk Van der Merwe
Pages: 170 - 175 - Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis(2024)
Authors: Wim Laleman
Pages: 156 - 165 - Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy-A Review of the Past Decade's Literature Focusing on Incidence, Risk Factors, and Prophylaxis(2024)
Authors: Wim Laleman
- Endoscopic procedures in hepatology: Current trends and new developments(2024)
Authors: Wim Laleman, Emma Vanderschueren
Pages: 124 - 139 - Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving b-blockers plus ligation to prevent re-bleeding(2024)
Authors: Wim Laleman, Frederik Nevens
- Epidemiology of liver transplantation and post-LT complications in Germany: nationwide study (2005-2018)(2023)
Authors: Wim Laleman
Pages: 1289 - 1297